Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.0
(2.35%)
USD 10.0
(2.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 40.6 Billion USD | 19.57% |
| 2023 | 33.95 Billion USD | 26.32% |
| 2022 | 26.87 Billion USD | 4.49% |
| 2021 | 25.72 Billion USD | 2.51% |
| 2020 | 25.09 Billion USD | 7.28% |
| 2019 | 23.39 Billion USD | -4.53% |
| 2018 | 24.5 Billion USD | 3.48% |
| 2017 | 23.67 Billion USD | -0.82% |
| 2016 | 23.87 Billion USD | 7.58% |
| 2015 | 22.19 Billion USD | 27.72% |
| 2014 | 17.37 Billion USD | 2.34% |
| 2013 | 16.97 Billion USD | 0.59% |
| 2012 | 16.87 Billion USD | 4.66% |
| 2011 | 16.12 Billion USD | 3.92% |
| 2010 | 15.51 Billion USD | 8.02% |
| 2009 | 14.36 Billion USD | 8.81% |
| 2008 | 13.2 Billion USD | 9.17% |
| 2007 | 12.09 Billion USD | 15.54% |
| 2006 | 10.46 Billion USD | 11.78% |
| 2005 | 9.36 Billion USD | 16.25% |
| 2004 | 8.05 Billion USD | 15.89% |
| 2003 | 6.95 Billion USD | 16.22% |
| 2002 | 5.98 Billion USD | 15.55% |
| 2001 | 5.17 Billion USD | 9.03% |
| 2000 | 4.74 Billion USD | 17.07% |
| 1999 | 4.05 Billion USD | 15.16% |
| 1998 | 3.52 Billion USD | 12.24% |
| 1997 | 3.13 Billion USD | 11.76% |
| 1996 | 2.8 Billion USD | 11.2% |
| 1995 | 2.52 Billion USD | 10.57% |
| 1994 | 2.28 Billion USD | 12.23% |
| 1993 | 2.03 Billion USD | 11.11% |
| 1992 | 1.83 Billion USD | 9.83% |
| 1991 | 1.66 Billion USD | 12.84% |
| 1990 | 1.47 Billion USD | 10.09% |
| 1989 | 1.34 Billion USD | 7.38% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 20.21 Billion USD | 196.83% |
| 2024 Q1 | 6.8 Billion USD | -1.69% |
| 2024 Q3 | 6.34 Billion USD | -68.59% |
| 2024 Q4 | 7.23 Billion USD | 13.89% |
| 2023 Q2 | 6.85 Billion USD | -47.66% |
| 2023 Q4 | 6.92 Billion USD | -1.98% |
| 2023 Q1 | 13.1 Billion USD | 81.17% |
| 2023 FY | 34.2 Billion USD | 25.32% |
| 2023 Q3 | 7.06 Billion USD | 3.03% |
| 2022 Q4 | 7.23 Billion USD | 4.95% |
| 2022 Q1 | 6.29 Billion USD | -4.58% |
| 2022 FY | 27.29 Billion USD | 11.02% |
| 2022 Q3 | 6.89 Billion USD | 6.64% |
| 2022 Q2 | 6.46 Billion USD | 2.72% |
| 2021 FY | 24.58 Billion USD | -9.09% |
| 2021 Q1 | 7.16 Billion USD | 25.37% |
| 2021 Q2 | 5.94 Billion USD | -16.97% |
| 2021 Q3 | 6.01 Billion USD | 1.18% |
| 2021 Q4 | 6.59 Billion USD | 9.55% |
| 2020 Q4 | 5.71 Billion USD | -25.21% |
| 2020 FY | 27.04 Billion USD | 7.14% |
| 2020 Q1 | 5.85 Billion USD | -7.78% |
| 2020 Q2 | 5.88 Billion USD | 0.46% |
| 2020 Q3 | 7.64 Billion USD | 29.9% |
| 2019 Q3 | 6.25 Billion USD | 0.19% |
| 2019 FY | 25.24 Billion USD | 2.74% |
| 2019 Q2 | 6.23 Billion USD | -0.05% |
| 2019 Q1 | 6.24 Billion USD | 1.0% |
| 2019 Q4 | 6.34 Billion USD | 1.58% |
| 2018 Q2 | 6.11 Billion USD | 1.61% |
| 2018 FY | 24.56 Billion USD | 3.49% |
| 2018 Q1 | 6.02 Billion USD | -3.28% |
| 2018 Q3 | 6.18 Billion USD | 1.05% |
| 2018 Q4 | 6.17 Billion USD | -0.06% |
| 2017 Q4 | 6.22 Billion USD | 10.63% |
| 2017 Q2 | 6.08 Billion USD | 7.29% |
| 2017 Q1 | 5.66 Billion USD | -5.75% |
| 2017 Q3 | 5.62 Billion USD | -7.46% |
| 2017 FY | 23.74 Billion USD | -0.71% |
| 2016 Q1 | 5.95 Billion USD | -6.49% |
| 2016 Q2 | 6 Billion USD | 0.94% |
| 2016 Q4 | 6.01 Billion USD | 1.95% |
| 2016 FY | 23.91 Billion USD | 5.93% |
| 2016 Q3 | 5.9 Billion USD | -1.78% |
| 2015 FY | 22.57 Billion USD | 25.45% |
| 2015 Q4 | 6.36 Billion USD | 4.67% |
| 2015 Q3 | 6.08 Billion USD | 8.36% |
| 2015 Q2 | 5.61 Billion USD | 32.27% |
| 2015 Q1 | 4.24 Billion USD | -2.28% |
| 2014 FY | 17.99 Billion USD | 2.56% |
| 2014 Q1 | 4.18 Billion USD | 1.43% |
| 2014 Q2 | 4.43 Billion USD | 5.93% |
| 2014 Q4 | 4.34 Billion USD | -1.7% |
| 2014 Q3 | 4.41 Billion USD | -0.38% |
| 2013 FY | 17.54 Billion USD | 3.94% |
| 2013 Q3 | 4.15 Billion USD | -5.42% |
| 2013 Q1 | 4.39 Billion USD | 3.41% |
| 2013 Q2 | 4.39 Billion USD | -0.05% |
| 2013 Q4 | 4.12 Billion USD | -0.67% |
| 2012 Q4 | 4.24 Billion USD | 2.61% |
| 2012 Q1 | 4.2 Billion USD | 10.54% |
| 2012 Q3 | 4.14 Billion USD | -3.34% |
| 2012 Q2 | 4.28 Billion USD | 1.9% |
| 2012 FY | 16.87 Billion USD | 4.66% |
| 2011 Q2 | 4.11 Billion USD | 2.82% |
| 2011 FY | 16.12 Billion USD | 3.92% |
| 2011 Q4 | 3.8 Billion USD | -9.52% |
| 2011 Q3 | 4.2 Billion USD | 2.09% |
| 2011 Q1 | 4 Billion USD | -0.99% |
| 2010 Q4 | 4.04 Billion USD | 3.16% |
| 2010 FY | 15.51 Billion USD | 8.02% |
| 2010 Q3 | 3.92 Billion USD | 2.86% |
| 2010 Q2 | 3.81 Billion USD | 1.87% |
| 2010 Q1 | 3.74 Billion USD | 2.66% |
| 2009 Q2 | 3.62 Billion USD | 4.16% |
| 2009 Q3 | 3.61 Billion USD | -0.39% |
| 2009 Q4 | 3.64 Billion USD | 0.86% |
| 2009 FY | 14.36 Billion USD | 8.81% |
| 2009 Q1 | 3.48 Billion USD | 4.13% |
| 2008 Q1 | 3.17 Billion USD | 0.86% |
| 2008 FY | 13.2 Billion USD | 9.17% |
| 2008 Q3 | 3.32 Billion USD | -0.68% |
| 2008 Q4 | 3.34 Billion USD | 0.57% |
| 2008 Q2 | 3.34 Billion USD | 5.32% |
| 2007 Q4 | 3.15 Billion USD | 4.28% |
| 2007 Q2 | 3.01 Billion USD | 3.84% |
| 2007 FY | 12.09 Billion USD | 15.54% |
| 2007 Q3 | 3.02 Billion USD | 0.24% |
| 2007 Q1 | 2.9 Billion USD | 6.27% |
| 2006 Q3 | 2.63 Billion USD | -0.11% |
| 2006 FY | 10.46 Billion USD | 11.78% |
| 2006 Q1 | 2.46 Billion USD | 2.16% |
| 2006 Q2 | 2.63 Billion USD | 7.22% |
| 2006 Q4 | 2.73 Billion USD | 3.67% |
| 2005 Q2 | 2.35 Billion USD | 6.76% |
| 2005 Q1 | 2.21 Billion USD | 5.34% |
| 2005 Q3 | 2.37 Billion USD | 0.81% |
| 2005 Q4 | 2.4 Billion USD | 1.26% |
| 2005 FY | 9.36 Billion USD | 16.25% |
| 2004 FY | 8.05 Billion USD | 15.89% |
| 2004 Q2 | 2.02 Billion USD | 7.04% |
| 2004 Q3 | 2.03 Billion USD | 0.22% |
| 2004 Q4 | 2.09 Billion USD | 3.21% |
| 2004 Q1 | 1.89 Billion USD | 6.25% |
| 2003 Q1 | 1.64 Billion USD | 6.6% |
| 2003 Q4 | 1.78 Billion USD | 0.81% |
| 2003 Q3 | 1.76 Billion USD | 0.82% |
| 2003 Q2 | 1.75 Billion USD | 6.81% |
| 2003 FY | 6.95 Billion USD | 16.22% |
| 2002 Q3 | 1.52 Billion USD | 0.83% |
| 2002 Q4 | 1.54 Billion USD | 1.19% |
| 2002 Q2 | 1.51 Billion USD | 7.44% |
| 2002 Q1 | 1.4 Billion USD | 6.08% |
| 2002 FY | 5.98 Billion USD | 15.55% |
| 2001 Q4 | 1.32 Billion USD | 1.47% |
| 2001 FY | 5.17 Billion USD | 9.03% |
| 2001 Q3 | 1.3 Billion USD | -0.59% |
| 2001 Q2 | 1.31 Billion USD | 6.78% |
| 2001 Q1 | 1.23 Billion USD | -11.76% |
| 2000 Q4 | 1.39 Billion USD | 22.52% |
| 2000 Q2 | 1.15 Billion USD | 8.5% |
| 2000 Q3 | 1.13 Billion USD | -1.22% |
| 2000 Q1 | 1.06 Billion USD | -11.2% |
| 2000 FY | 4.74 Billion USD | 17.07% |
| 1999 Q4 | 1.19 Billion USD | 21.49% |
| 1999 Q1 | 904 Million USD | -11.63% |
| 1999 FY | 4.05 Billion USD | 15.16% |
| 1999 Q2 | 968.6 Million USD | 7.15% |
| 1999 Q3 | 984.4 Million USD | 1.63% |
| 1998 Q4 | 1.02 Billion USD | 21.35% |
| 1998 Q2 | 854 Million USD | 6.62% |
| 1998 Q3 | 843 Million USD | -1.29% |
| 1998 Q1 | 801 Million USD | -11.52% |
| 1998 FY | 3.52 Billion USD | 12.24% |
| 1997 Q2 | 766.6 Million USD | 8.32% |
| 1997 Q4 | 905.3 Million USD | 19.53% |
| 1997 FY | 3.13 Billion USD | 11.76% |
| 1997 Q1 | 707.7 Million USD | -13.04% |
| 1997 Q3 | 757.4 Million USD | -1.2% |
| 1996 Q3 | 674.9 Million USD | -1.17% |
| 1996 FY | 2.8 Billion USD | 11.2% |
| 1996 Q1 | 635.2 Million USD | -12.9% |
| 1996 Q2 | 682.9 Million USD | 7.51% |
| 1996 Q4 | 813.8 Million USD | 20.58% |
| 1995 Q1 | 576.9 Million USD | -13.55% |
| 1995 Q4 | 729.3 Million USD | 21.25% |
| 1995 Q3 | 601.5 Million USD | -2.43% |
| 1995 Q2 | 616.5 Million USD | 6.86% |
| 1995 FY | 2.52 Billion USD | 10.57% |
| 1994 FY | 2.28 Billion USD | 12.23% |
| 1994 Q1 | 518.4 Million USD | -13.25% |
| 1994 Q4 | 667.3 Million USD | 23.14% |
| 1994 Q3 | 541.9 Million USD | -2.41% |
| 1994 Q2 | 555.3 Million USD | 7.12% |
| 1993 Q3 | 479 Million USD | -3.49% |
| 1993 Q4 | 597.6 Million USD | 24.76% |
| 1993 Q2 | 496.3 Million USD | 7.56% |
| 1993 Q1 | 461.4 Million USD | -13.89% |
| 1993 FY | 2.03 Billion USD | 11.11% |
| 1992 Q1 | 412.6 Million USD | -15.02% |
| 1992 Q4 | 535.8 Million USD | 23.4% |
| 1992 FY | 1.83 Billion USD | 9.83% |
| 1992 Q2 | 448.3 Million USD | 8.65% |
| 1992 Q3 | 434.2 Million USD | -3.15% |
| 1991 Q4 | 485.5 Million USD | 21.13% |
| 1991 Q1 | 375.7 Million USD | -0.71% |
| 1991 Q2 | 405 Million USD | 7.8% |
| 1991 FY | 1.66 Billion USD | 12.84% |
| 1991 Q3 | 400.8 Million USD | -1.04% |
| 1990 Q3 | 369.8 Million USD | -1.86% |
| 1990 Q1 | 351.5 Million USD | 106.86% |
| 1990 FY | 1.47 Billion USD | 10.09% |
| 1990 Q2 | 376.8 Million USD | 7.2% |
| 1990 Q4 | 378.4 Million USD | 2.33% |
| 1989 FY | 1.34 Billion USD | 7.38% |
| 1989 Q4 | -5.12 Billion USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q2 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -16317.041% |
| Dynavax Technologies Corporation | 219.14 Million USD | -18426.546% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -7574.699% |
| Perrigo Company plc | 1.52 Billion USD | -2556.199% |
| Illumina, Inc. | 3.81 Billion USD | -964.778% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | -295.943% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -8902.357% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -1877.594% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -33549.104% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -1342.12% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -90794.844% |
| Waters Corporation | 943.51 Million USD | -4203.049% |
| Biogen Inc. | 5.2 Billion USD | -680.034% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -17654.067% |
| Evolus, Inc. | 189.75 Million USD | -21295.56% |
| Adicet Bio, Inc. | 152.03 Million USD | -26603.85% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -28398.628% |
| bluebird bio, Inc. | 240.23 Million USD | -16800.33% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -14832.125% |
| FibroGen, Inc. | 398.11 Million USD | -10098.11% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -1819.622% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -291783.881% |
| Homology Medicines, Inc. | 9.87 Million USD | -411039.241% |
| Geron Corporation | 70.44 Million USD | -57536.888% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -2155.479% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -9393.723% |
| Myriad Genetics, Inc. | 600.1 Million USD | -6665.539% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -40166.992% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -7260.86% |
| Zoetis Inc. | 2.76 Billion USD | -1368.354% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -83607.888% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -3626.856% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -2224.949% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | -750.262% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -103595.758% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -5107.886% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -14626.526% |
| Verastem, Inc. | 92.08 Million USD | -43990.179% |
| Nektar Therapeutics | 190.9 Million USD | -21167.345% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -8422.966% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -334304.085% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -2883.502% |
| OPKO Health, Inc. | 574.68 Million USD | -6964.728% |
| Exelixis, Inc. | 1.58 Billion USD | -2458.647% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -2443.063% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -10914.291% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -72717.275% |
| uniQure N.V. | 285.08 Million USD | -14141.317% |
| Imunon, Inc. | 21.03 Million USD | -192953.589% |
| Blueprint Medicines Corporation | 722.86 Million USD | -5516.571% |
| Insmed Incorporated | 949.26 Million USD | -4177.011% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -13464.169% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -9831.361% |
| TG Therapeutics, Inc. | 198.47 Million USD | -20355.977% |
| Incyte Corporation | 1.19 Billion USD | -3310.346% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -3788.889% |